All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
CDK inhibitors
CDK inhibitors
Cyclin-dependent kinase (CDK) pathways are often dysregulated in AML. CDKs control cell-cycle progression and gene transcription. Inhibiting CDKs can lead to downregulation of cell survival genes which are regulated by MCL-1, MYC, and cyclin D1. CDK9 is one target of therapeutic agents in AML. CDK inhibitors such as alvocidib, dinaciclib, and TG02 are in clinical development.
Save to your areas of interest